What's happening
This bill decriminalizes the possession of buprenorphine in New York State.
Why it matters
Removes criminal penalties for possessing buprenorphine, a medication used to treat opioid use disorder, which could reduce barriers for people seeking help with addiction.
May decrease the risk of arrest and incarceration for individuals carrying buprenorphine, potentially encouraging more people to use it as part of their recovery process.
Could help reduce the stigma and fear associated with seeking treatment for opioid use disorder, as people would no longer have to worry about legal consequences for possessing a key treatment medication.
Aligns with harm reduction efforts, aiming to address the opioid crisis by making evidence-based treatment options more accessible and less risky legally.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
People possessing buprenorphine
The bill would remove buprenorphine from the Penal Law definitions of controlled substance and narcotic preparation, eliminating possession liability under provisions that rely on those definitions.
Police and district attorneys
The bill would narrow the substances covered by drug offenses that rely on those definitions, changing the basis for buprenorphine arrests and prosecutions.
Criminal defense attorneys and public defenders
The exclusions would affect their representation of clients facing buprenorphine charges under provisions that use those definitions.
Headline styles
Decriminalize Buprenorphine Possession
Plain English, a few words. Used as the page title.
Sponsors
History
- Referred to codes
- Committed to rules
- Advanced to third reading
- 2nd report cal.
- 1st report cal.866
- Print number 699a
- Amend and recommit to codes
- Referred to codes
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Allow Buprenorphine Possession
In Assembly Committee · Codes · Sponsor Linda Rosenthal
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
699--A
2023-2024 Regular Sessions
IN SENATE
January 6, 2023
Introduced by Sens. RIVERA, BRISPORT, COMRIE, COONEY, GONZALEZ, GOUNARDES, HOYLMAN-SIGAL, JACKSON, KENNEDY, MYRIE, RAMOS, SALAZAR -read twice and ordered printed, and when printed to be committed to the Committee on Codes -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee
AN ACT to amend the penal law, in relation to decriminalizing the possession of buprenorphine
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subdivisions 5 and 8 of section 220.00 of the penal law, subdivision 5 as amended by chapter 92 of the laws of 2021 and subdivision 8 as amended by section 18 of part C of chapter 447 of the laws of 2012, are amended to read as follows:
5. "Controlled substance" means any substance listed in schedule I, II, III, IV or V of section thirty-three hundred six of the public health law other than buprenorphine.
8. "Narcotic preparation" means any controlled substance listed in schedule II(b-1), III(d) or III(e), other than buprenorphine.
§ 2. This act shall take effect on the first of November next succeeding the date on which it shall have become a law.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD01963-02-3
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the penal law, in relation to decriminalizing the possession of buprenorphine
Purpose
This bill would exclude buprenoiphine, a medication commonly used to treat opioid use disorder, from the list of controlled substances.
Summary of specific provisions
Section 1 amends section 220.00 of the penal law by adding buprenorphine as an exception under the definition for controlled substances.
Section 2 sets forth the effective date.
Justification
Buprenorphine is an effective medication used to treat opioid use disor- der (OUD). In 2000, the federal Drug Addiction Treatment Act allowed physicians to begin prescribing buprenorphine for treatment of OUD, which provided them with an option other than methadone for the treat- ment and management of OUD. Buprenorphine is classified as a schedule III/IIIN controlled substance because its potential for abuse is marked- ly lower than methadone. Additionally, because patients can self-admin- ister buprenorphine, it does not require patients to travel to doctors' offices or treatment facilities each day for their prescribed dose.
Despite its efficacy, buprenorphine is classified as a controlled substance, meaning that individuals who possess it without a prescription risk criminal prosecution, even if they are using it to treat their own opioid use disorder. While there is a small risk that people may divert and use buprenorphine, the vast majority of use, both subsequent to a prescription and not, is to manage opioid use disorder. We should not discourage this use.
This legislation would place buprenorphine on par with marijuana in our schedule of controlled substances and ensure we are not wrongly prose- cuting individuals who are attempting to treat an opioid use disorder.
Legislative history
2019-2020: A10109 Rosenthal L / No Same-As
2021-2022: S2524 / A612 Rosenthal L
Fiscal implications
None.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.